NCT03620786 is a clinical trial of Sonablate HIFU device in Prostate Cancer, sponsored by University of California, Los Angeles.

Who is sponsoring NCT03620786?

NCT03620786 is sponsored by University of California, Los Angeles.

What drugs are being tested in NCT03620786?

Interventions in NCT03620786: Sonablate HIFU device.

What condition does NCT03620786 study?

NCT03620786 studies Prostate Cancer.

Is NCT03620786 still recruiting?

NCT03620786 is currently recruiting now. Last updated 16 April 2026.

Last reviewed 2026-04-16 · How we verify

NCT03620786

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HIFU for Focal Ablation of Prostate Tissue: An Observational Study

Recruiting now Last updated 16 April 2026

What this trial tests

trial testing Sonablate HIFU device in Prostate Cancer in 100 participants. Currently enrolling.

Timeline

26 September 2018

Primary endpoint
31 January 2027

31 January 2028

Quick facts

Lead sponsor	University of California, Los Angeles
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	100
Start date	26 September 2018
Primary completion	31 January 2027
Estimated completion	31 January 2028
Sites	1 location across United States

Drugs / interventions tested

Sonablate HIFU device

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

University of California, Los Angeles

Who can join

Adults 40 to 85, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The Sonablate HIFU device was approved by the U.S.FDA for prostate tissue ablation in October, 2015. The purpose of this observational research study is to investigate the localized treatment of prostate cancer using HIFU through clinical data and health-related quality of life (HRQOL) questionnaires.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Immunomodulation and targeted drug delivery with high intensity focused ultrasound (HIFU): Principles and mechanisms.
Ashar H, Ranjan A. · · 2023 · cited 41× · PMID 36965581 · DOI 10.1016/j.pharmthera.2023.108393
Focal ablation therapy presents promising results for selectively localized prostate cancer patients.
Feng D, Li D, Xiao Y, Wu R, et al · · 2023 · cited 22× · PMID 37691892 · DOI 10.21147/j.issn.1000-9604.2023.04.08
Therapeutic ultrasound transducer technology and monitoring techniques: a review with clinical examples.
Lafond M, Payne A, Lafon C. · · 2024 · cited 4× · PMID 39134055 · DOI 10.1080/02656736.2024.2389288
Focal therapy, time to join the multi-disciplinary team discussion?
Reddy D, Bedi N, Dudderidge T. · · 2020 · cited 2× · PMID 32676440 · DOI 10.21037/tau.2019.09.30
Evolution of Active Surveillance of Prostate Cancer: Impact of Magnetic Resonance Imaging, Magnetic Resonance Imaging-Guided Biopsy, and Focal Therapy.
Martin SC, Gonzalez S, Kwan L, Delfin M, et al · · 2025 · cited 1× · PMID 40257918 · DOI 10.1097/ju.0000000000004559

Verify or expand the search:

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other University of California, Los Angeles trials

Trials by the same sponsor.

NCT04846517 — rTMS for Aneroxia Nervosa in Youth · NA · not yet recruiting
NCT06701760 — Sodium Lactate in Severe TBI · Phase 2 · not yet recruiting
NCT04996667 — Effect of iNO in Patients With Submassive and Massive PE · Phase 2 · withdrawn
NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
NCT07534696 — Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03620786 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Los Angeles
Last refreshed: 16 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03620786.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing